MedTrace Logo

Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC

NCT05725915 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2023-02-13

No results posted yet for this study

Summary

The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.

Conditions

  • Lung Cancer, Nonsmall Cell

Sponsors & Collaborators

  • Beijing Red Clove Public Welfare Development Center

    lead OTHER

Principal Investigators

  • Shuhua Han, docter · Southeast University Zhongda Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-09-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725915 on ClinicalTrials.gov